Fast Company November 18, 2021
Ruth Reader

Sherlock Biosciences’ first-ever use of CRISPR in a diagnostic has huge potential for at-home COVID-19 testing and beyond.

This article is about one of the honorees of Fast Company’s first Next Big Things in Tech awards. Read about all the winners here.

In January 2020, CRISPR startup Sherlock Biosciences was in the middle of working on CRISPR-based tests that could deliver lab quality testing at home for common illnesses like flu or sexually transmitted infections like chlamydia or gonorrhea. When COVID-19 struck, the company quickly got to work on a lab test for it.

Within two months, the company submitted its CRISPR-based test to the Food and Drug Administration for emergency use authorization. In May, the FDA gave its authorization,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Home, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
How GLP-1’s moved from research labs to national TV
Understanding the politics of drug pricing in the United States
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it
Brazil’s plan for low-cost CAR-Ts

Share This Article